1245319-54-3

Basic information

• Product Name: 4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide
• Synonyms: 4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide;4-(5-aMino-2-(pyridin-3-yl)thiazolo[5,4-d]pyriMidin-7-yl)-N-p-tolylpiperazine-1-carboxaMide;PI4KIII beta inhibitor 3;PI4KIII β inhibitor 3
• CAS NO: 1245319-54-3
• Molecular Formula: C₂₂H₂₂N₈OS
• Molecular Weight: 446.52808
• Product Categories: PI3K/Akt/mTOR;Akt;mTOR;PI3K
• Mol File: 1245319-54-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.432±0.06 g/cm3(Predicted)
• PKA: 13.95±0.70(Predicted)
• CAS DataBase Reference: 4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide(1245319-54-3)
• EPA Substance Registry System: 4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide(1245319-54-3)

Safety Data

• Hazardous Substances Data: 1245319-54-3(Hazardous Substances Data)

Usage

General Description

4-(5-Amino-2-pyridin-3-yl-thiazolo[5,4-d]pyrimidin-7-yl)-piperazine-1-carboxylic acid p-tolylamide is a chemical compound with potential pharmaceutical applications. It is a piperazine derivative that contains an amino-pyridinyl-thiazolopyrimidinyl moiety, making it a potential candidate for drug development. The presence of the p-tolylamide group suggests that it may have bioactive properties and could potentially interact with biological receptors or enzymes. Further research and testing are needed to fully understand the pharmaceutical potential of this compound and its possible uses in medicine.

Upstream product

• 500-22-1 3-pyridinecarboxaldehyde 
• 1211527-74-0 7-chlorothiazolo[5,4-d]pyrimidin-5-amine 
• 171887-03-9 N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide 
• 622-58-2 p-Tolylisocyanate 
• 1435953-80-2 4-(5-aminothiazolo[5,4-d]pyrimidin-7-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 1435953-79-9 4-[2-amino-6-chloro-5-(formylamino)pyrimidin-4-yl]piperazine-1-carboxylic acid tert-butyl ester 
• 1262121-06-1 tert-butyl 4-(5-amino-2-(pyridin-3-yl)thiazolo[5,4-d]pyrimidin-7-yl)piperazine-1-carboxylate 
• 1245319-93-0 tert-butyl 4-(2,5-diamino-6-mercaptopyrimidin-4-yl)piperazine-1-carboxylate 
• 1245319-92-9 tert-butyl 4-(2,5-diamino-6-chloropyrimidin-4-yl)piperazine-1-carboxylate 
• 1245317-63-8 5-amino-2-(3-pyridinyl)thiazolo[5,4-d]pyrimidine-7-thiol 
• 1245319-52-1 7-(piperazin-1-yl)-2-(pyridin-3-yl)thiazolo[5,4-d]pyrimidin-5-amine 

Relevant articles and documents

Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able to Significantly Prolong Allogeneic Organ Engraftment in Vivo

The primary target of a novel series of immunosuppressive 7-piperazin-1-ylthiazolo[5,4-d]pyrimidin-5-amines was identified as the lipid kinase, PI4KIIIβ. Evaluation of the series highlighted their poor solubility and unwanted off-target activities. A medicinal chemistry strategy was put in place to optimize physicochemical properties within the series, while maintaining potency and improving selectivity over other lipid kinases. Compound 22 was initially identified and profiled in vivo, before further modifications led to the discovery of 44 (UCB9608), a vastly more soluble, selective compound with improved metabolic stability and excellent pharmacokinetic profile. A co-crystal structure of 44 with PI4KIIIβ was solved, confirming the binding mode of this class of inhibitor. The much-improved in vivo profile of 44 positions it as an ideal tool compound to further establish the link between PI4KIIIβ inhibition and prolonged allogeneic organ engraftment, and suppression of immune responses in vivo.

Antiviral Activity of Novel Bicyclic Heterocycles

The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.